^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD22 positive

i
Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Entrez ID:
Related biomarkers:
21d
Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia. (PubMed, Hematol Rep)
Case presentation: Herein, we present the case of a 23-month-old girl with high-risk B-ALL who experienced very early isolated medullary relapse; following the failure of conventional chemotherapy according to the ALL-IC REL 2016 protocol, she went on to receive the bispecific T-cell engager (BiTE) blinatumomab and subsequently, due to refractory disease, the combination of fludarabine, cytarabine, and the proteasome inhibitor bortezomib without achieving remission. The minimal residual disease (MRD) was 0.08% on day 28, and InO was continued, thus achieving MRD negativity; the patient successfully underwent an allogeneic stem cell transplantation from a matched family donor. Our case highlights the efficacy and safety of InO as a salvage treatment in the setting of relapsed B-ALL refractory not only to conventional chemotherapy but also to novel treatments, such as blinatumomab and bortezomib.
Journal
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression • CD22 overexpression
|
cytarabine • bortezomib • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • fludarabine IV
29d
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL (clinicaltrials.gov)
P2, N=28, Completed, Zhejiang University | Recruiting --> Completed | Phase classification: P1/2 --> P2 | N=50 --> 28 | Trial completion date: Mar 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
Trial completion • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
1m
Development and Characterization of A Novel SpyTagged Modular Nanobody as A Detection Platform for CD22-Positive Cells. (PubMed, Cell J)
The novel FITC-SpyC-SpyT-CD22Nb produced in the present study is capable of detecting the surficial expression of CD22. According to our findings, FITC-SpyC-SpyT-CD22Nb is applicable for specific targeting of CD22 in a therapeutic manner, i.e., chimeric antigen receptor (CAR)-T cell therapy and antibody drug conjugates (ADCs).
Journal • IO biomarker
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
7ms
Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD20 expression • CD22 positive
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
7ms
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). (clinicaltrials.gov)
P2, N=20, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Apr 2024
Enrollment open • Trial initiation date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • azacitidine
7ms
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P3, N=310, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • ITGB1 (Integrin Subunit Beta 1)
|
CD20 positive • CD22 positive
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine
7ms
INO-FIRST: Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO (clinicaltrials.gov)
P=N/A, N=158, Recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Not yet recruiting --> Recruiting
Enrollment open
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
7ms
High yield killing of lymphoma cells by anti-CD22 CAR-NK cell therapy. (PubMed, In Vitro Cell Dev Biol Anim)
m971-CD28-CD3ζ NK-92 cells efficiently lysed CD22-expressing lymphoma cell lines and produced large amounts of cytokines such as IFN-γ and GM-CSF but a lower level of IL-6 after coculturing with target cells. Based on our results, it is evident that transferring m971-CD28-CD3ζ NK-92 cells could be a promising immunotherapy for B cell lymphoma.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CD28 (CD28 Molecule) • CSF2 (Colony stimulating factor 2)
|
CD22 positive • CD22 expression
8ms
Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia-A Podcast. (PubMed, Target Oncol)
Several ongoing trials in older patients with newly diagnosed ALL have yielded encouraging data with inotuzumab ozogamicin in induction alone and in combination with low-intensity chemotherapy. In this podcast, the authors summarize and highlight some of the recent findings on the use of inotuzumab ozogamicin as induction therapy for older adults with newly diagnosed ALL.
Journal
|
TP53 (Tumor protein P53) • CD22 (CD22 Molecule)
|
TP53 mutation • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
8ms
IRB-50836: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Stanford University | Trial completion date: Dec 2024 --> Dec 2037
Trial completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
9ms
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)
P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2023 --> May 2024
Trial completion date • Trial primary completion date • Post-transplantation
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • CD22 positive • BCL2 rearrangement
|
Besponsa (inotuzumab ozogamicin)
9ms
A041703: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=64, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
9ms
INO-FIRST: Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO (clinicaltrials.gov)
P=N/A, N=158, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | N=250 --> 158 | Trial completion date: Jun 2024 --> Nov 2024 | Initiation date: Nov 2023 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Nov 2024
Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
9ms
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (clinicaltrials.gov)
P1, N=10, Active, not recruiting, Stanford University | Suspended --> Active, not recruiting | N=52 --> 10 | Trial completion date: Aug 2035 --> Sep 2036 | Trial primary completion date: Aug 2025 --> Oct 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
9ms
ADCT-602, a novel PBD dimer-containing antibody-drug conjugate for treating CD22-positive hematological malignancies. (PubMed, Mol Cancer Ther)
Combining ADCT-602 + pacritinib was beneficial in ADCT-602-resistant cells. Chidamide increased CD22 expression on B-cell tumor surfaces, increasing ADCT-602 activity. These data support clinical testing of ADCT-602 in R/R B-ALL (NCT03698552) and CD22-positive hematological cancers.
Journal
|
CD22 (CD22 Molecule) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1)
|
CD22 positive • CD22 expression
|
Epidaza (chidamide) • Vonjo (pacritinib) • epratuzumab-cys-tesirine (ADCT-602)
10ms
IRB-50836: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
P1, N=52, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=92 --> 52 | Trial completion date: Sep 2034 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
11ms
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
11ms
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=24, Recruiting, Shanxi Province Cancer Hospital | Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide
12ms
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL (clinicaltrials.gov)
P1, N=19, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial completion date: Aug 2022 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Nov 2023
Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Minimal residual disease
|
CD22 (CD22 Molecule)
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells
12ms
Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults (ASH 2023)
All patients received fludarabine (FLU) and cyclophosphamide (CTX) conditioning chemotherapy (FLU 30mg/m 2, d1-3; CTX 500mg/m 2, d1-3) before CAR-T infusions. In summary, CD19/CD22 exhibited a manageable safety but limited antileukemia activity. Our study showed that mixture of CD19 CAR-T and CD22 CAR-T cells infusion is fail to expected to compensate for the treatment of relapsed in r/r ALL and prolonging the leukemia-free survival of patients. The low-efficacy of dual-targeted CAR-T cells may be caused by the CAR19 and CAR22 cells interfere with each other and weaken the CAR-T amplification in vivo.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • IL2 (Interleukin 2) • CD27 (CD27 Molecule) • CASP9 (Caspase 9)
|
CD19 expression • CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV
12ms
Combining Inotuzumab Ozogamicin (IO) with PARP Inhibitors, Olaparib and Talazoparib, Exerts Synergistic Cytotoxicity By Inhibiting the Repair of IO-Induced DNA Strand Breaks in IO-Resistant ALL Cells (ASH 2023)
This would be because the PARP inhibitors were still effective in inhibiting the DNA repair in Reh-IO-R cells where the DNA repair function was not augmented. [Conclusion]The combination of IO with PARP inhibitors synergized the antileukemic effect of IO by inhibiting DNA strand break repair in CD22-positive ALL cell lines and IO-resistant ALL cells, suggesting that these results may contribute to overcoming the IO resistance mechanisms.
BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ERCC1 (Excision repair cross-complementation group 1) • CD22 (CD22 Molecule) • CHEK1 (Checkpoint kinase 1) • ANXA5 (Annexin A5)
|
ABCB1 overexpression • CD22 positive • CD22 expression • ATM expression
|
Lynparza (olaparib) • Talzenna (talazoparib) • Besponsa (inotuzumab ozogamicin)
12ms
Enrollment closed
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
Trial completion date • Head-to-Head
|
TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A) • CD22 (CD22 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
KMT2A rearrangement • MLL rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
Clinical • P1 data • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone
1year
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL. (PubMed, J Clin Oncol)
Inotuzumab ozogamicin-based induction followed by age-adapted chemotherapy was well tolerated and resulted in high rates of remission and OS. These data provide a rationale for integrating inotuzumab ozogamicin into first-line regimens for older patients with B-ALL.
Clinical • Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
New P2 trial • CAR T-Cell Therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
1year
CD19CD22 CAR-T Therapy in Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P2, N=20, Not yet recruiting, The First Affiliated Hospital of Soochow University
New P2 trial
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • azacitidine
1year
Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia responding to retreatment with inotuzumab ozogamicin (PubMed, Rinsho Ketsueki)
A 72-year-old man with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) was treated with dasatinib (week1: 50 mg/day, week2: 70 mg/day, week3-: 100 mg/day) and prednisolone from June 2017...Although the treatment was changed to ponatinib 30 mg/day, he experienced a second relapse in June 2018...Because the patient was still CD22-positive, InO was given again, and the patient achieved CR at the end of the second cycle. We had a case where re-administering InO was effective as a salvage therapy for relapsed/refractory Ph+ALL (r/r Ph+ALL) in an elderly patient.
Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
|
dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin)
1year
Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies. (PubMed, Eur J Haematol)
This study has generated a novel bispecific CAR-T cell that can simultaneously target CD19 or CD22 positive tumor cells, providing a new strategy to address the limitations of single-targeted CAR-T therapy in B-cell tumors (limited response or relapse).
Journal • CAR T-Cell Therapy • IO biomarker
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression • CD22 positive
1year
New trial
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
1year
ALL 001: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (clinicaltrials.gov)
P1, N=36, Active, not recruiting, University of Virginia | Recruiting --> Active, not recruiting | Trial completion date: Jul 2028 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • Oncaspar liquid (pegaspargase)
1year
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov)
P1/2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=30 --> 0 | Trial completion date: Aug 2023 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Nov 2022
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • CAR T-Cell Therapy • Metastases • Immune cell
|
CD22 (CD22 Molecule)
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
over1year
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P1/2, N=44, Recruiting, Leland Metheny | Trial primary completion date: Jun 2023 --> Dec 2023
Trial primary completion date • Post-transplantation
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
|
BCL6 rearrangement • CD22 positive • BCL2 rearrangement
|
Besponsa (inotuzumab ozogamicin)
over1year
Trial completion • Enrollment change
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
over1year
Study of Sequential CAR-T Cell Treating Leukemia Children (clinicaltrials.gov)
P2, N=100, Active, not recruiting, Beijing Boren Hospital | Recruiting --> Active, not recruiting
Enrollment closed • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
|
CD19 expression • CD22 positive • CD22 expression
|
cyclophosphamide
over1year
Efficient chimeric antigen receptor (CAR) targeting of a central epitope of CD22. (PubMed, J Biol Chem)
Side-by-side comparisons indicated that while IS7-CAR killed less rapidly than m971-CAR in vitro, it remains efficient in controlling lymphoma xenograft models in vivo. Thus, IS7-CAR presents a potential alternative candidate for treatment of refractory B-cell malignancies.
Journal
|
CD22 (CD22 Molecule)
|
CD22 positive
over1year
Trial primary completion date • Enrollment open
|
CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
|
CD20 expression • CD22 positive
|
clonoSEQ
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
over1year
Trial completion
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
over1year
Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
P1, N=26, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2023 --> Jul 2024
Trial primary completion date • Combination therapy
|
CD22 (CD22 Molecule)
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin)
over1year
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=24, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Jun 2023
Trial completion • Trial completion date
|
CD22 (CD22 Molecule)
|
CD22 positive • CD22 expression
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin
over1year
EU PIP Study: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (clinicaltrials.gov)
P2, N=100, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2027 --> Jun 2028
Enrollment open • Trial completion date • Trial primary completion date • Head-to-Head
|
TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A) • CD22 (CD22 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
KMT2A rearrangement • MLL rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)